Alprazolam absorption kinetics affects abuse liability
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the behavioral, subjective, and reinforcing effects of immediate-release (IR) alprazolam and extended-release (XR) alprazolam to assess the effect of release rate on laboratory measures of abuse liability. METHODS: Fourteen healthy men with histories of sedative abuse participated as subjects in a double-blind crossover study. All subjects received placebo, 1 and 2 mg immediate-release alprazolam, and 2 and 3 mg extended-release alprazolam in random order. Behavioral performance, subjective effects, and alprazolam plasma concentrations were assessed repeatedly 1/2 hour before and 1/2, 1, 3, 5, 7, 9, 12, and 24 hours after drug administration. RESULTS: Mean peak alprazolam plasma concentrations occurred 1.7 and 9.2 hours after immediate-release alprazolam and extended-release alprazolam, respectively. Compared to placebo, 2 mg immediate-release alprazolam impaired all measures of psychomotor and cognitive performance (Digit Symbol Substitution Test), motor coordination (circular lights and balance), and memory (digit entry and recall); 2 mg extended-release alprazolam did not affect any of these measures and 3 mg extended-release alprazolam impaired circular lights only. Immediate-release alprazolam, 2 mg, increased all six measures of positive drug effects (e.g., ratings of liking or good effects); none of these measures were increased by 2 mg extended-release alprazolam and only three of the six measures were increased by 3 mg extended-release alprazolam. A drug versus money multiple-choice procedure designed to assess the relative reinforcing effects of each condition was administered 24 hour after the drug. The amount of money subjects were willing to "pay" to take the drug was significantly greater than placebo for both doses of immediate-release alprazolam but for neither dose of extended-release alprazolam. CONCLUSIONS: These data indicate that extended-release alprazolam has less potential for abuse than immediate-release alprazolam.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alprazolam-XR at a dose of 2 mg per day did not increase any of the same 6 measures of positive drug effects, but 3 mg per day increased 3 of the 6 measures, mainly “liking” and “good effects.””
From A Review of Alprazolam Use, Misuse, and Withdrawal (2018) · cites this paper as Mumford et al., 1995
In the citing paper
“Participants were willing to pay more money to retake alprazolam compared with placebo for both immediate and extended-release formulations (Mumford et al., 1995).”
From A Review of Alprazolam Use, Misuse, and Withdrawal (2018) · cites this paper as Mumford et al., 1995
In the citing paper
“In a study of 14 outpatients with a history of sedative misuse, alprazolam immediate-release (IR) at 2 and 1 mg doses increased all 6 measures of positive drug effects, including ratings of “liking,” “good effects,” and “strength.””
From A Review of Alprazolam Use, Misuse, and Withdrawal (2018) · cites this paper as Mumford et al., 1995
Citations
Cites
Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943
An automated version of the digit symbol substitution test (DSST)
McLeod, D. R., Griffiths, R. R., Bigelow, G. E., & Yingling, J. (1982) · Behavior Research Methods & Instrumentation · doi:10.3758/bf03203313 · Cited by 365
FIXED‐INTERVAL SCHEDULE OF COCAINE REINFORCEMENT: EFFECT OF DOSE AND INFUSION DURATION1
Balster, R. L., & Schuster, C. R. (1973) · Journal of the Experimental Analysis of Behavior · doi:10.1901/jeab.1973.20-119 · Cited by 290
Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans.
Griffiths, R. R., Troisi, J., Silverman, K., & Mumford, G. K. (1993) · PubMed · Cited by 172
Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.
Evans, S. M., Funderburk, F. R., & Griffiths, R. R. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23193-7 · Cited by 165
Benzodiazepine and sedative use/abuse by methadone maintenance clients
Iguchi, M. Y., Handelsman, L., Bickel, W. K., & Griffiths, R. R. (1993) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(93)90090-d · Cited by 152
Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans
Griffiths, R., Troisi, J. R., Silvermian, K., & Miumford, G. K. (1993) · Behavioural Pharmacology · doi:10.1097/00008877-199302000-00001 · Cited by 129
Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
Smith, R. B., Kroboth, P. D., VanderLugt, J. T., Phillips, J. P., & Juhl, R. P. (1984) · Psychopharmacology · doi:10.1007/bf00431449 · Cited by 126
Rate of increase of plasma drug level influences subjective response in humans
de Wit, H., Bodker, B., & AMBRE, J. J. (1992) · Psychopharmacology · doi:10.1007/bf02245161 · Cited by 125
Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo.
Griffiths, R. R., Bigelow, G. E., Liebson, I., & Kaliszak, J. E. (1980) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32353-0 · Cited by 116
Research works printed but not linked: 11
- Fischman M. W., 1984, Fed Proc, 43, 570
- Griffiths R. R., 1984, J Pharmacol Exp Ther, 229, 501
- Sellers E. M., 1993, J Clin Psychiatry, 54, 64
- Ciraulo D. A., 1988, J Clin Psychiatry, 49, 333
- Guarino J. J., 1988, Pharmacologist, 30, A196
- Wright C. E., 1991, Pharm Res, 10, S250
- Griffiths R. R., 1979, J Pharmacol Exp Ther, 210, 301
- Griffiths R. R., 1980, J Pharmacol Exp Ther, 215, 649
- Roache J. D., 1985, J Pharmacol Exp Ther, 234, 120
- Roache J. D., 1987, J Pharmacol Exp Ther, 243, 978
- Evans S. M., 1990, J Pharmacol Exp Ther, 255, 1246
Cited by
Camí, J., & Farré, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023160 · Cited by 477
Opioid dependence and addiction during opioid treatment of chronic pain
Ballantyne, J. C., & LaForge, S. K. (2007) · Pain · doi:10.1016/j.pain.2007.03.028 · Cited by 447
Jacobs, E. A., & Bickel, W. K. (1999) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.7.4.412 · Cited by 356
Griffiths, R. R., & Weerts, E. M. (1997) · Psychopharmacology · doi:10.1007/s002130050422 · Cited by 260
Self-citationBehavioral Pharmacology of Zolpidem Relative to Benzodiazepines A Review
Rush, C. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00102-6 · Cited by 260
Metadata
- Authors
- Mumford, G. K., Evans, S. M., Fleishaker, J. C., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1995-03
- Volume
- 57
- Issue
- 3
- Pages
- 356-365
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2047501424
- Cited by
- 63
- References
- 30
- Citations by year
- 2024: 2 · 2023: 3 · 2020: 1 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 3 · 2012: 7
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (DA03889, R01DA003889)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- alprazolam, sustained-release formulation, immediate-release formulation, drug release rate, abuse liability, sedative abuse, plasma drug concentration, psychomotor performance, cognitive performance, subjective drug effects, drug reinforcement
- MeSH terms
- Adult, Alprazolam, Analysis of Variance, Cognition, Delayed-Action Preparations, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Male, Psychomotor Performance, Surveys and Questionnaires, Reference Values, Time Factors, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alprazolam absorption kinetics affects abuse liability. https://app.cochat.ai/papers/10.1016/0009-9236(95)90162-0
- The paper
- Mumford, G. K., Evans, S. M., Fleishaker, J. C., & Griffiths, R. R. (1995). Alprazolam absorption kinetics affects abuse liability. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/0009-9236(95)90162-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.